Centre for the Advancement of Sustainable Medical Innovation

CASMI
Founded 2012
Focus Medical innovation, pharmaceutical R&D, life science regulation
Key people
 Sir John Bell, Sir John Tooke, Dr Richard Barker
Website www.casmi.org.uk

The Centre for the Advancement of Sustainable Medical Innovation (CASMI)[1] is a collaboration between University of Oxford and University College London, created to develop new models for medical innovation. The centre aims to address the issues that have led to current failures in the translation of basic bioscience into affordable and widely adopted new treatments.

Leadership

Sir John Bell – Co-chair
Sir John Tooke – Co-chair
Richard Barker – Director

Fellows

Oxford Fellows

Professor Houman Ashrafian
Professor Chas Bountra
Professor Sir Rory Collins
Professor Kay Davies
Professor Sue Dopson
Professor Andrew Farmer
Professor Adrian Hill
Professor Stephen MacMahon
Professor Robyn Norton
Professor Michael Parker
Professor Len Seymour
Professor Hugh Watkins

UCL Fellows

Professor Nick Freemantle
Professor Dame Hazel Genn
Professor Aroon Hingorani
Professor Robert Horne
Professor Philip Luthert
Professor Quentin Pankhurst
Professor Rosalind Raine
Professor David Taylor
Professor Bryan Williams
Professor Martin Utley

Projects

Adaptive licensing

CASMI is leading an evaluation of whether the UK would be a suitable test site for a potential adaptive licensing[2] pilot through the European Medicines Agency. This was recently announced in the government's ‘Strategy for UK Life Sciences: One Year On’ report.[3] The project was initiated by a workshop held at the Wellcome Trust on 2 April 2012.

Stratified medicine

CASMI is developing recommendations on how the regulatory environment and pharmaceutical R&D process should be adapted to the needs of stratified medicine[4] and companion diagnostics.

Regulation of cell therapy

CASMI, supported by the Technology Strategy Board, is investigating current and anticipated regulatory obstacles to the successful commercialisation of cell-based therapies, seeking to integrate the opinion of key stakeholders to support the development of a sustainable and globally competitive UK cell therapy industry.[5]

Partners

SENS Foundation
Technology Strategy Board
University of Oxford
UCL
Wellcome Trust

Recent publications

Adaptive drug development and licensing, Richard Barker & Sarah Garner, Regulatory Rapporteur. Oct 2012[6]
A flexible blueprint for the future of drug development, Richard Barker, Lancet. Jan 2010[7]

References

  1. ↑ "CASMI website". CASMI. Retrieved 2013-01-28.
  2. ↑ "Adaptive licensing project page, CASMI website". CASMI. Retrieved 2013-01-28.
  3. ↑ http://www.bis.gov.uk/assets/biscore/innovation/docs/s/12-1346-strategy-for-uk-life-sciences-one-year-on.pdf |title=Industrial Strategy: government and industry in partnership |author=HM Government
  4. ↑ "Stratified medicine project page, CASMI website". CASMI. Retrieved 2013-01-28.
  5. ↑ "Cell-based therapies project page, CASMI website". CASMI. Retrieved 2013-01-28.
  6. ↑ http://www.aptivsolutions.com/wp-content/uploads/2012/09/Regulatory-Rapporteur-October-2012.pdf |agency=Regulatory Rapporteur |coauthors=Dr Richard Barker, Sarah Garner
  7. ↑ Original TextRichard Barker a. "A flexible blueprint for the future of drug development". The Lancet. Retrieved 2013-01-28.
This article is issued from Wikipedia - version of the Monday, April 20, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.